Navigation Links
Promise and Problems Signal Mixed Year Ahead for Biopharmaceutical Industry, Says Pharmaceutical Executive Magazine
Date:2/21/2013

NEW YORK, Feb. 21, 2013 /PRNewswire/ -- Biopharmaceuticals – the major source of new medicines and a key knowledge industry for the future – faces another rough year from empowered payers as it makes its slow passage to a renewed product base. This is the main finding from Pharmaceutical Executive magazine's annual survey of trends and issues facing the biopharma world in the year ahead. The annual outlook has run continuously in our January issue since the magazine was founded in 1981, and is based on interviews with more than 20 top opinion leaders and experts drawn from business and the clinical professions as well as the regulatory, patient and payer communities.

"Our mission is to take the pulse of the 'c suite' of top management and other external decision-makers who collectively determine the future of this vital industry," said Pharm Exec Content Director William Looney . "This is a business that develops more than 90 per cent of medicines in current use and adds considerably to economic output in an era where the high paying jobs it generates are increasingly scarce."   

The 2013 Industry Forecast reviewed an uptick of FDA and EMA approvals over the past two years to conclude that company labs are beginning to leverage the fruits of the revolution in molecular biology and science's successful mapping of the human genome. A key factor is the growing ability of the industry to translate academic insights about the origins of diseases into development pathways that lead to commercialization. The best science is meaningless if it cannot lead to a medicine, vaccine or device that is safe and effective for patient use – finally, big Pharma is recognizing it cannot do all of this alone.  

The Forecast highlights that this year marks an important difference from past cycles of discovery. "Our interviews detect far more pessimism about how quickly new innovations will be taken up in actual clinical practice," Looney said. "Payers, led by governments with significant budgetary cost exposures, are proving far more skeptical about the science and want more evidence that discoveries will not only benefit individual patients but deliver a broader public health outcome too." The forecast notes that defining such outcomes is firmly in in the eye of the beholder, which puts a premium on information that is relevant, accessible, clean and unbiased.

Delivering new products that make sense to budget conscious payers is more important than ever, as other sources of growth are under significant stress. In particular, the shine is off the so-called emerging markets of Asia and the developing world, largely because local competition to big Pharma is becoming more intense. And while it is clear that government funders in the US, Europe and Japan are tightening their pocketbooks on drug reimbursement, less is understood about the long term implications of the failure of the these critical mainstay markets to invest in the basic infrastructure for research and wise regulation that biopharma companies depend on to remain globally productive. "More than ever, the industry has to make the case for itself, which historically is a task it has neglected – the assumption is that innovation will always be rewarded," warns the Pharm Exec Forecast. "2013 is the year that so-called truth will be tested."  

For the full text of the 2013 Pharm Exec Industry Forecast, visit our web site, pharmexec.com

For further information on the magazine and our full range of information services, please contact Pharm Exec's Publisher, Russ Pratt , at rpratt@advanstar.com

Contact:
Bill Looney
Editor in Chief
blooney@advanstar.com  
212-951-6735

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Pharmaceutical Executive Magazine
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
2. Contract Research Organisations offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan
3. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
4. New Study Shows Promise For Women Needing Mesh-Augmented Pelvic Organ Prolapse (POP) Repair
5. Data Underscore Promise of Satori Pharmaceuticals Gamma-Secretase Modulator Program in Treatment of Alzheimers Disease
6. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
7. Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimers Disease
8. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
9. Only Podiatric Surgeon In S. Florida That Performs In-Office Ultrasound Imaging On Foot & Ankle Problems Saving Patients Over $1,000 In MRI Expenses & Extra Trip To Hospital
10. The Hygenic Corporations Custom Rubber Solutions Solve Industry Problems
11. Problems With the Stryker Rejuvenate Hip System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
(Date:4/27/2016)... 27, 2016 At the Sachs ... of a Phase 2 clinical study of its lead ... undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, ... Germany and France ... at the time of surgery. "Despite advances in cochlear ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip meals occasionally (which is ... was among the many new lifestyle diet tips offered by nutritionists Pam Bonney and ... of Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, ...
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
Breaking Medicine News(10 mins):